This is the second time in three months that a patient suffering from bone marrow failure was successfully treated with its PLX cells, the Israeli company ... failed bone marrow transplants, sending its stock up 32 percent.
New York, NY -- (SBWIRE) -- 07/25/2017 -- Proven efficacious as an antidote for Acute Radiation Syndrome (ARS) with data recently published from studies conducted by the U.S. National Institutes of Health (NIH), Pluristem Therapeutics' …
SBWire10mon
Protalix BioTherapeutics, Inc. PLX announced that the European Commission (“EC ... But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% …
Pluristem said it will start preparations to keep an emergency stock of PLX-R18 on hand for use in such events. Full approval of the drug will depend on the results of a Phase III clinical trial. Pluristem said on Monday it is in discussions …
PLX stands for placenta expanded and 18 for the word chai ... Pluristem is traded on both the Israeli stock exchange and on Nasdaq in the US. The company has a $200 million market capitalization, and gets about $4 million annually from …
Among the companies with shares expected to actively trade in Tuesday’s session are PLX Technology Inc. (PLXT), P.F. Chang’s China Bistro Inc. (PFCB) and Emerson Electric Co. (EMR). Integrated Device Technology Inc. (IDTI) said it will …
PLX-R18's development for ARS appears to be in the most capable ... Sachs & Co. in 1963 where he was established …
SBWire9mon
Pluristem Therapeutics Inc. (Nasdaq: PSTI) today announced the publication of a scientific study regarding PLacental …
Among the companies with shares expected to actively trade in Monday’s session are Integrys Energy Group Inc., PLX Technology Inc. and Corinthian Colleges Inc.